Overview

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
0
Participant gender:
All
Summary
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Amir Moheet
Treatments:
Empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Criteria
Inclusion Criteria:

- Adult subjects 18 years or older with CFRD and on insulin treatment

- BMI >25 kg/m2

- A participant who is capable of becoming pregnant must agree to take precautions that
are effective in preventing pregnancy throughout this study. These methods could
include one of the following 1. Complete abstinence from sexual intercourse; 2. Tubal
ligation; 3. Use combination of two forms of contraception during the study including,
oral, injectable, or implanted hormonal contraceptives, intrauterine device or barrier
method.

Exclusion Criteria:

- acute pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids
within 4 weeks prior to baseline study procedures

- less than 12 weeks since start of a new CFTR corrector/modulator therapy

- type 1 diabetes

- Positive GAD 65 antibody or low fasting C-peptide (below the normal reference range of
the lab)

- A history of diabetic ketoacidosis

- history of recurrent genital or urinary tract infections

- pregnancy or lactation

- prior solid organ transplant

- Chronic liver disease (based on problem list in medical records or alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times elevated above
the upper limit of normal.

- chronic kidney disease (eGFR < 60mL/min/1.73 m2)

- Hypersensitivity to empagliflozin or any excipients of Jardiance

- History of eating disorder

- Non-English speakers and those unable to read in English • Diminished capacity to
consent (study staff will utilize the MacCAT-CR for assessment)